A
ALTx Therapeutics
First-in-class precision oncology targeting immortal cancer cell pathways.
About ALTx Therapeutics
ALTx Therapeutics is a UK-based biotechnology startup focused on the discovery and development of first-in-class precision oncology medicines. The company specifically targets the Alternative Lengthening of Telomeres (ALT) pathway, a unique survival mechanism that allows cells in up to 15% of all cancers to achieve cellular immortality. By developing novel inhibitors for this cancer-specific biological process, ALTx aims to provide highly targeted treatments for patients suffering from aggressive tumors, including rare, pediatric, and brain cancers that currently have limited therapeutic options.
Read full description
The company was spun out of the Francis Crick Institute and is built upon the foundational discoveries of its scientific founder, Simon Boulton, a globally recognized expert in DNA damage repair and telomere maintenance. Initially incorporated under the Slingshot accelerator umbrella, ALTx Therapeutics officially launched in February 2026 with a £12.55 million seed funding round. This financing was backed by leading life sciences investor Syncona, alongside the Francis Crick Institute and Cancer Research Horizons, to provide the necessary infrastructure to transition academic breakthroughs into tangible therapies.
Currently operating as a flagship venture within Syncona’s Slingshot platform, ALTx Therapeutics is rapidly advancing its pipeline of novel drug targets from pre-clinical research toward clinical readiness. The firm’s overarching mission is to leverage fundamental discovery science to strip aggressive tumors of their immortality mechanisms, ultimately delivering life-changing clinical outcomes and addressing critical unmet needs within the modern oncology landscape.
At a glance
- Status
- Operational
- Founded
- 2026
- Headquarters
- Houghton and Wyton, United Kingdom
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, Woman Founder, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Feb 2026 | $13M | $50M | Cancer Research Horizon · The Francis Crick Institute · Syncona | ↗ |
| SPINOUT✓Other financing | Feb 2026 | $0 | — | The Francis Crick Institute | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
The Francis Crick Institute
Cancer Research Horizon
Syncona
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ALTx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ALTx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.